Conditions: Sezary Syndrome Pruritus
Keywords: Sezary Syndrome Pruritus Aprepitant Neurokinin-1
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 7
Healthy volunteers: no

Brief summary:
The purpose of this randomized, double-blinded, placebo-controlled study is to test the hypothesis that administration of aprepitant will decrease the severity of pruritus in patients with Sèzary Syndrome.

Detailed description:

Arms:
arm 1: Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days. arm 2: Matching placebo will be given in place of aprepitant

Interventions: intervention 1: Aprepitant intervention 2: Placebo
Intervention descriptions: intervention 1: Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days. intervention 2: Placebo will be given orally for a total of 7 days.

Protocol document: